When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome–positive B‐cell acute lymphoblastic leukemia | Zendy

Cassaday Ryan D. | Zendy

Premium

When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome–positive B‐cell acute lymphoblastic leukemia

Author(s) -

Cassaday Ryan D.

Publication year - 2020

Publication title -

cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.052

H-Index - 304

eISSN - 1097-0142

pISSN - 0008-543X

DOI - 10.1002/cncr.32565

Subject(s) - blinatumomab , medicine , propensity score matching , lymphoblastic leukemia , philadelphia chromosome , oncology , randomized controlled trial , refractory (planetary science) , cancer , leukemia , chromosomal translocation , genetics , gene , biology , astrobiology

A randomized controlled trial of blinatumomab for the treatment of patients with Philadelphia chromosome–positive B‐cell acute lymphoblastic leukemia is unlikely. In this issue of Cancer , Rambaldi et al perform a propensity score analysis to provide a comparison with historical standards of care.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research